Clinical Trial Protocol ATM-[ADDRESS_625697]-2022 Confidential Page 1/[ADDRESS_625698]-2022 Confidential Page 2/[ADDRESS_625699] a prior written approval and require an amendment or administrative letter.    Approved by [CONTACT_2728] ‚Äì ACOM Labs Inc.  ___________________________  ______________________________  Printed Name [CONTACT_1641]    ___________________________  ______________________________   Signature [CONTACT_486915] [CONTACT_486900] - ethica CRO Inc.  ___________________________  ______________________________  Printed Name [CONTACT_1641]    ___________________________  ______________________________   Signature [CONTACT_1782]         !&(
  "$!""$!"!%""' # 
% $!&(

	

Clinical Trial Protocol ATM-[ADDRESS_625700]-2022 Confidential Page 3/25  
 INVESTIGATOR SIGNATURE [CONTACT_1783]  I agree to: ‚Ä¢ Implement and conduct this study diligently and in strict compliance with the protocol, good clinical practices and all applicable laws and regulations. ‚Ä¢ Maintain all information supplied by [CONTACT_486901], Inc. in confidence and, when this information is submitted to an Institutional Review Board (IRB) or another group, it will be submitted with a designation that the material is confidential.    I have read this protocol in its entirety and I agree to all aspects.          Principal Investigator (Printed Name)  Signature  [CONTACT_486916]-[ADDRESS_625701]-2022 Confidential Page 4/25  
 SYNOPSIS Version Version 2.0 (28-Oct-2022) Study Device Intradermal needle adapter Study Number ATM-[ADDRESS_625702] Not Applicable Indication Inflammatory Acne Lesions Study Sites 1 site (US) Title Intralesional Injections of Triamcinolone for Acne Vulgaris Sponsor ACOM Labs, Inc. Study Duration  [ADDRESS_625703] Sample Size ~[ADDRESS_625704]-of-care intralesional injection with triamcinolone using an intradermal needle adapter at Visit 1 (Day 1). Subjects will then attend in-clinic visits at Visit 2 (24-hours post-injection), Visit 3 (48-hours post-injection), Visit 4 (72-hours post-injection), Visit 5 (Day 7), and Visit 6 (Day 14). Efficacy assessments (target lesion assessments, photography) and safety assessments will be conducted by [CONTACT_486902]. Subjects will conduct lesion pain assessments at each study visit as well as satisfaction assessments at each post-treatment visit. Study Objectives The objective of this proof-of-concept study is to investigate the safety of using an intradermal needle adapter for performing intralesional injections. Inclusion Criteria 1. Outpatient, male or female of any race, [ADDRESS_625705] one (1) identifiable inflammatory lesion that, in the opi[INVESTIGATOR_871], is clinically indicated for standard-of-care intralesional injection(s) of triamcinolone and for which the research participant has already agreed to have standard-of-care intralesional injection(s) of triamcinolone. 4. Able to follow study instructions and likely to complete all required visits. 5. In good general health as determined by [CONTACT_486903] (Investigator discretion). 6. Sign the IRB-approved ICF (including HIPAA authorization) prior to any study-related procedures being performed. Exclusion Criteria 1. Female subjects who are pregnant or breast-feeding. 2. Known hypersensitivity or previous allergic reaction to any constituent of triamcinolone injection. 3. Active cutaneous viral infection in any treatment area at Baseline. 4. Have concomitant skin disease or infection (other than acne) or presence of skin comorbidities in the areas of skin where study device will be used. 5. History of poor cooperation or unreliability (Investigator discretion). 6. Planning to move out of the area prior to study completion. 7. Subjects who are investigational site staff members or family members of such employees. 8. Exposure to any other investigational /device within 30 days prior to Visit 1. Study Treatment Intradermal Needle Adapter: The intradermal needle adapter is an accessory that slips on the end of a standard 32G 0.5‚Äù needle and reduces the effective length of the needle to 1mm. The adapter is made of biocompatible [ADDRESS_625706]-2022 Confidential Page 5/[ADDRESS_625707] manner for typi[INVESTIGATOR_486869]. Triamcinolone for Injection: A commercial supply of triamcinolone for injection will be used for injection. The site will store triamcinolone as per the conditions described in the package insert. A standard 32G 0.5‚Äù needle will be fixed to a 1.0 mL luer syringe and the syringe will be loaded with an appropriate volume and concentration of triamcinolone. A total of 0.05 mL to 0.15 mL of triamcinolone 0.5% to 2.5% will be injected into each target lesion. The choice of volume and concentration will be at the discretion of the Investigator as per his clinical judgement. An intradermal needle adapter will then be installed on the needle. At least one (1), and up to three (3) inflammatory target lesions will be selected for intralesional injections of triamcinolone using the intradermal needle adapter. Blinding Not applicable  Investigator Assessments ‚Ä¢ Global Severity Score (GSS): A 5-point scale assessing ranging from 0 (Clear) to 4 (Severe). Note: only Baseline assessments will be conducted. ‚Ä¢ Target Lesion Erythema: A 5-point scale ranging from 0 (No Erythema) to 4 (Very Severe Erythema). ‚Ä¢ Target Lesion Severity: A 5-point scale ranging from 0 (None) to 4 (Very Severe). ‚Ä¢ Target Lesion Improvement: A 7-point scale ranging from 1 (Clear; 100%) to 7 (Worse). ‚Ä¢ Target Lesion Videography: A video will be taken of each injected lesion starting from just prior to needle penetration and up to 10 seconds after removed of needle from lesion. ‚Ä¢ Target Lesion Photography: Photographs will be taken at each study visit of each injected inflammatory lesion. At Baseline, photographs will be taken both pre- and post-injection. Subject Assessments ‚Ä¢ Target Lesion Pain: Target lesion pain will be self-assessed by [CONTACT_48681] a Visual Analog Scale  ‚Ä¢ Intralesional Injection Pain: Target lesion injection pain will be self-assessed by [CONTACT_48681] a Visual Analog Scale. ‚Ä¢ Subject Satisfaction: A 5-point scale ranging from 1 (Very satisfied) to 4 (Very dissatisfied). Safety Endpoints Adverse Events Sample Size Approximately 20 subjects will be enrolled. This is a POC study and a formal sample size justification is not provided for this study. It is the opi[INVESTIGATOR_486870] a total of 20 subjects will be sufficient to achieve the objective of the study. Statistical Methods For categorical parameters, the number and percentage of subjects/observations in each category will be presented. The denominator will be based on the number of subjects/observations appropriate for the purpose of analysis. For continuous parameters, descriptive statistics will include n (number of subjects or observations), mean, standard deviation, median, and range. Two-sided 95% CIs will be provided for all study outcomes. The modified Intent-to-Treat (mITT) Population (defined as all subjects who were enrolled and received at least one application with the study device) will be used for analyses of safety and effectiveness endpoints. A Per-Protocol (PP) Population will neither be defined nor analyzed.   
Clinical Trial Protocol ATM-[ADDRESS_625708]-2022 Confidential Page 6/25  
 SCHEDULE OF EVENTS AND PROCEDURES Visit Number V1 V2 V3 V4 V5 V6 Day/Week/Month Day [ADDRESS_625709]-Inj. Day 7 ¬±1 day Day 14 ¬±2 days Assessment and Procedures       Informed Consent X      Inc/Excl Criteria X      Demographics, Med Hx X      Concomitant Medications X X X X X X Intralesional Injection(s) X      Investigator Assessments       Global Severity Score X      Target Lesion Assessments X X X X X X Target Lesion Photography X pre-/post- inj. X X X X X Lesion Injection Videography X      Subject Assessments       Target Lesion Pain X pre-inj. X X X X X Intralesional Injection Pain X post- inj.      Subject Satisfaction  X X X X X Safety Assessments       UPT (as applicable) X      Adverse Events X X X X X X    
Clinical Trial Protocol ATM-[ADDRESS_625710]-2022 Confidential Page 7/[ADDRESS_625711] NUMBERING, RANDOMIZATION AND BLINDING ........................................................ 11 7 CONCOMITANT AND PROHIBITED MEDICATION/PROCEDURES ............................................ [ADDRESS_625712] MANAGEMENT .............................................................................. 11 8.1 Intradermal Needle Adapter .................................................................................................................. 11 8.2 Triamcinolone for Injection ................................................................................................................... 12 9 STUDY EVALUATIONS ............................................................................................................................ 12 9.1 Visit Procedures ..................................................................................................................................... 12 9.1.1 Visit 1 (Baseline; Day 1) ...................................................................................................................................... 12 9.1.2 Visits 2 to 6 (24hr , 48hr, 72hr, 7 days, 14 days) ................................................................................................. 13 9.2 Investigator Assessments ....................................................................................................................... 13 9.2.1 Global Severity Score (GSS) ................................................................................................................................ 13 9.2.2 Target Lesion Assessments .................................................................................................................................. 13 [IP_ADDRESS] Target Lesion Erythema ......................................................................................................................... 13 [IP_ADDRESS] Target Lesion Severity ............................................................................................................................ 14 [IP_ADDRESS] Target Lesion Improvement ................................................................................................................... 14 [IP_ADDRESS] Target Lesion Videography .................................................................................................................... 14 [IP_ADDRESS] Target Lesion Photography ..................................................................................................................... [ADDRESS_625713] Satisfaction .............................................................................................................................................. 15 9.4 Safety ..................................................................................................................................................... 15 9.4.1 Adverse Events .................................................................................................................................................... 15 [IP_ADDRESS] Definition of Adverse Event ................................................................................................................... 15 [IP_ADDRESS] Documenting Adverse Experiences ........................................................................................................ 15 [IP_ADDRESS] Serious Adverse Events .......................................................................................................................... 16 [IP_ADDRESS] Assessment of Severity ........................................................................................................................... 16 [IP_ADDRESS] Assessment of Causality ......................................................................................................................... 16 [IP_ADDRESS] Reporting of Serious Adverse Events ..................................................................................................... 17 [IP_ADDRESS] Pregnancy ............................................................................................................................................... 17 10 STATISTICS ................................................................................................................................................ 17 10.1 Sample Size Determination ................................................................................................................... 18 10.2 Assessment of Safety ............................................................................................................................. 18 10.2.1 Adverse Events .................................................................................................................................................... 18 10.2.2 Concomitant Medications .................................................................................... Error! Bookmark not defined. 10.3 Analysis Populations ............................................................................................................................. 18 10.3.1 Intent-to-Treat (ITT) Population .......................................................................................................................... 18 10.3.2 Per-Protocol (PP) Population ............................................................................................................................... [ADDRESS_625714]-2022 Confidential Page 8/[ADDRESS_625715] Data Protections ........................................................................................................................ 20 12.5 Data Monitoring Committee .................................................................................................................. 21 12.6 Investigator Obligation .......................................................................................................................... 21 12.7 Changes to the Protocol ......................................................................................................................... 21 12.8 Confidentiality Regarding Study Subjects ............................................................................................ 21 12.9 Reporting and Publication of Results .................................................................................................... 21 12.10 Financing and Insurance ........................................................................................................................ 21 13 APPENDICES .............................................................................................................................................. 22 APPENDIX A: PROTOCOL VERSION HISTORY ............................................................................... 22 APPENDIX B: ADJUSTMENT OF VISITS AND ASSESSMENTS DUE TO COVID-[ADDRESS_625716]-2022 Confidential Page 9/[ADDRESS_625717] of care therapy for stubborn acne lesions. They are typi[INVESTIGATOR_486871] 0.5 mg/mL to 2.5 mg/mL (i.e., 0.5% to 2.5%) in volumes of 0.[ADDRESS_625718] 32G 0.5‚Äù needle and reduces the effective length of the needle to 1mm. The adapter (currently a prototype) is made of biocompatible [ADDRESS_625719] the safety of the intradermal needle adapter, not the safety and efficacy of triamcinolone per-se. 2 STUDY OBJECTIVE The objective of this proof-of-concept study is to investigate the safety of using an intradermal needle adapter for performing intralesional injections. 3 COMPLIANCE STATEMENT The study will be conducted in accordance with the Clinical Investigation Plan, International Conference on Harmonization (ICH) and Good Clinical Practice (GCP), the Declaration of Helsinki, International Organization for Standardization (ISO) [ZIP_CODE], and the [LOCATION_002] (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, and 21 CFR Part 312). In addition, the study will be conducted in compliance with all applicable laws and regulatory requirements relevant to the use of new medical devices in the [LOCATION_002]. The sites‚Äô Principal Investigator (PI) is responsible for ensuring the privacy, safety and welfare of the subjects during and after the study and must ensure that site personnel are appropriately trained. The PI [INVESTIGATOR_486872], and for contact [CONTACT_262855], and local authorities.  3.1 Variations to the Protocol No changes from the final approved (signed) protocol will be initiated without the prior approval by [CONTACT_486904] 1) when necessary to eliminate immediate hazards to the subjects or when the change involves only logistics or administration, or 2) minor administrative or typographical corrections. The sites‚Äô PIs and the Sponsor must sign any protocol amendments. 3.2 Investigational Sites One (1) U.S. investigational site will participate in this study. The site must obtain written approval from a [ADDRESS_625720]-2022 Confidential Page 10/[ADDRESS_625721]-of-care intralesional injection with triamcinolone using an intradermal needle adapter at Visit 1 (Day 1). Subjects will then attend in-clinic visits at Visit 2 (24-hours post-injection), Visit 3 (48-hours post-injection), Visit 4 (72-hours post-injection), Visit 5 (Day 7), and Visit 6 (Day 14). 5 STUDY POPULATION Potential study participants may be identified and recruited into the study through various methods, such as: ‚Ä¢ Database of individuals who have agreed to be contact[CONTACT_7678]; ‚Ä¢ In-person recruitment; ‚Ä¢ Physician to physician referrals; ‚Ä¢ Internet advertisement; ‚Ä¢ Print advertisement. Note that scripts and advertisement fliers will be submitted to the IRB as necessary. 5.[ADDRESS_625722] a negative UPT at Baseline. A female is considered of childbearing potential unless she is: - postmenopausal for at least 12 months prior to study device administration; - without a uterus and/or both ovaries; or - has been surgically sterile for at least [ADDRESS_625723] one (1) identifiable inflammatory lesion that, in the opi[INVESTIGATOR_871], is clinically indicated for indicated for standard-of-care intralesional injection(s) of triamcinolone and for which the research participant has already agreed to have standard-of-care intralesional injection(s) of triamcinolone. 4. Able to follow study instructions and likely to complete all required visits. 5. In good general health as determined by [CONTACT_486903] (Investigator discretion). 6. Sign the IRB-approved ICF (including HIPAA authorization) prior to any study-related procedures being performed. 5.[ADDRESS_625724]-2022 Confidential Page 11/[ADDRESS_625725] concomitant skin disease or infection (other than acne) or presence of skin comorbidities in the areas of skin where study device will be used. 5. History of poor cooperation or unreliability (Investigator discretion). 6. Planning to move out of the area prior to study completion. 7. Subjects who are investigational site staff members or family members of such employees. 8. Exposure to any other investigational /device within [ADDRESS_625726] be carefully documented by [CONTACT_978] [INVESTIGATOR_486873], CRF, and (if applicable), on the AE form.  [ADDRESS_625727] number; new subjects will be allocated a new subject number. Screen Failures will not be entered in the eCRF. 7 CONCOMITANT AND PROHIBITED MEDICATION/PROCEDURES 7.1 Concomitant Medications and Procedures All treatment/procedures received by [CONTACT_486905], including the name [CONTACT_12169]/procedure, must be recorded in the CRF with end dates, if applicable. Every attempt should be made to keep concomitant therapy dosing constant during the study. Any change to concomitant therapy should be noted in source documents and the CRF. There are no prohibited medications defined for the study. Any necessary therapi[INVESTIGATOR_486874]. Subjects currently taking medications to treat acne should be instructed to maintain their current dosing throughout the study. [ADDRESS_625728] 32G 0.5‚Äù needle and reduces the effective length of the needle to 1mm (Figure 1). The adapter is made of biocompatible [ADDRESS_625729]-2022 Confidential Page 12/25  
  Figure 1. Intradermal Needle Adapter 8.2 Triamcinolone for Injection A commercial supply of triamcinolone 10% for injection will be provided to the site and diluted with Saline to the appropriate concentration. The site will store triamcinolone as per the conditions described in the package insert. A standard 32G 0.5‚Äù needle will be fixed to a 1.0 mL luer syringe and the syringe will be loaded with an appropriate volume and concentration of triamcinolone. A total of 0.05 mL to 0.15 mL of triamcinolone 0.5% to 2.5% will be injected into each target lesion. The choice of volume and concentration for each individual lesion will be at the discretion of the Investigator as per his clinical judgement. The intradermal needle adapter will then be installed on the needle. At least one (1), and up to three (3) inflammatory target lesions will be selected for intralesional injections of triamcinolone using the intradermal needle adapter. 9 STUDY EVALUATIONS 9.1 Visit Procedures 9.1.1 Visit 1 (Baseline; Day 1) ‚Ä¢ Written informed consent (incl. HIPAA and [LOCATION_004] Bill of Rights) ‚Ä¢ Inclusion / exclusion criteria ‚Ä¢ UPT (if female subject of childbearing potential) ‚Ä¢ Medical history and demographics ‚Ä¢ Concomitant medications/treatments ‚Ä¢ Investigator Assessments - Global Severity Score (GSS) - Target Lesion Assessments: lesion erythema, lesion severity - Target Lesion Photography (pre- and post-injection) - Target Lesion Injection Videography ‚Ä¢ Subject Assessments - Target lesion pain (pre-injection) - Intralesional injection pain (post-injection) ‚Ä¢ Intralesional injection(s) ‚Ä¢ AE Assessment 

Clinical Trial Protocol ATM-[ADDRESS_625730]-2022 Confidential Page 13/25  
 9.1.2 Visits 2 to 6 (24hr, 48hr, 72hr, 7 days¬±1 day, 14 days¬±2 days) ‚Ä¢ Investigator Assessments - Target Lesion Assessments: lesion erythema, lesion severity, improvement - Target Lesion Photography ‚Ä¢ Subject Assessments - Target lesion pain - Subject Satisfaction ‚Ä¢ Concomitant medications/treatments ‚Ä¢ AE Assessment  9.2 Investigator Assessments 9.2.1 Global Severity Score (GSS) The Investigator will use the following GSS scale to determine subjects‚Äô Baseline acne severity (Table 1).  Table 1: Global Severity Score Score Grade Description [ADDRESS_625731] Clear Rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyperpi[INVESTIGATOR_49194], though not pi[INVESTIGATOR_8745]-red 2 Mild Some non-inflammatory lesions are present, with few inflammatory lesions (papules/pustules only; no nodulocystic lesions) 3 Moderate Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, and there may or may not be one nodulocystic lesion 4 Severe Inflammatory lesions are more apparent, many comedones and papules/pustules, there may or may not be up to 2 nodulocystic lesions  9.2.2 Target Lesion Assessments Up to 3 inflammatory lesions on the face will be chosen for intralesional injections of triamcinolone using the study device as per Section 8 (i.e., target lesions). Each injected lesion will be individually assessed as per the following methods. [IP_ADDRESS] Target Lesion Erythema The Investigator will use the following scale to determine the severity of erythema for each target lesion (Table 2).  Table 2: Target Lesion Erythema Grade Description [ADDRESS_625732]-2022 Confidential Page 14/25  
 [IP_ADDRESS] Target Lesion Severity The Investigator will determine the severity of each target lesion as per the scale in Table 3.  Table 3: Target Lesion Severity Grade Description 0 None 1 Mild 2 Moderate 3 Severe 4 Very Severe  [IP_ADDRESS] Target Lesion Improvement  The Investigator will determine the improvement seen with each target lesion as per the scale in Table 4.  Lesion improvement will not be assessed at Baseline. Table 4: Target Lesion Improvement Grade Description 1 Clear (100%) [ADDRESS_625733] clear (90% to <100%) 3 Marked improvement (75% to <90%) 4 Moderate improvement (50% to <75%) 5 Fair improvement (25% to <50%) 6 No change 7 Worse  [IP_ADDRESS] Target Lesion Videography  A video will be taken of each injected lesion starting from just prior to needle penetration and up to 10 seconds after removed of needle from lesion. [IP_ADDRESS] Target Lesion Photography Photographs will be taken at each study visit of each injected inflammatory lesion. At Baseline, photographs will be taken both pre- and post-injection. 9.[ADDRESS_625734] using a 10 cm Visual Analog Scale (VAS) Pain Scale. Lesion pain at Baseline will be recorded prior to injection(s). The occurrence of inflammatory lesion pain is expected and will not be considered an AE. 9.3.[ADDRESS_625735] using the Visual Analog Scale (VAS). Lesion pain at Baseline will be recorded prior to injection(s). Injection Site Pain during injection will be assessed for all injected lesions immediately after the final lesion has been injected. Ten (10) minutes after these assessments, injection pain will be assessed again for all injected lesions.  The occurrence of injection site pain is expected and will not be considered an AE. 
Clinical Trial Protocol ATM-[ADDRESS_625736]-2022 Confidential Page 15/[ADDRESS_625737] will be instructed: ‚ÄúRate your level of satisfaction with the effect of study treatment on inflammatory acne lesions by [CONTACT_63080]‚Äù: Table 5.  Subject Satisfaction Scale Grade Description 1 Very satisfied 2 Satisfied 3 Neither satisfied nor dissatisfied 4 Dissatisfied 5 Very dissatisfied 9.4 Safety  9.4.1 Adverse Events All observed or volunteered AEs regardless of suspected causal relationship to the study device will be recorded in the CRF. Subjects will be questioned for the occurrence of any new or worsening signs or symptoms at each visit. [IP_ADDRESS] Definition of Adverse Event An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a study device and which does not necessarily have a causal relationship with the study device. AEs include any unfavorable and unintended illness, sign, symptom, clinically significant laboratory test abnormality, or disease temporally associated with the use of a study device that has appeared or worsened during the course of the clinical trial, regardless of causal relationship to the study device under study. The collection of non-serious AEs and serious adverse events (SAEs) will begin following the subject's signature [CONTACT_56534]. [IP_ADDRESS] Documenting Adverse Experiences The PI [INVESTIGATOR_486875]. AEs should be documented as a single medical diagnosis. When this is not possible, AEs should be documented in terms of signs/symptoms observed by [CONTACT_978] [INVESTIGATOR_486876]. Each AE that appears to be independent of any prior event will be reported separately. All AEs occurring after the subject signs the informed consent form through the last study visit must be reported, regardless of AE causality. All AEs, whether in response to a query, observed by [CONTACT_3991], or reported spontaneously by [CONTACT_423], will be recorded.  At each visit during the study, the subject will be assessed for the occurrence of new and ongoing AEs. The following data will be collected on all AEs and recorded on the appropriate CRF: ‚Ä¢ Event name (diagnosis preferred, if unknown, record the signs/symptoms) ‚Ä¢ Onset date and end date ‚Ä¢ Maximum intensity (severity) ‚Ä¢ Seriousness ‚Ä¢ Action taken regarding study device ‚Ä¢ Corrective treatment, if given 
Clinical Trial Protocol ATM-[ADDRESS_625738]-2022 Confidential Page 16/25  
 ‚Ä¢ Outcome ‚Ä¢ Investigator assessment of causality [IP_ADDRESS] Serious Adverse Events All AEs will be assessed as either serious or non-serious. An SAE is defined as any untoward medical occurrence that at any dose: ‚Ä¢ Results in death ‚Ä¢ Is immediately life threatening, (the term "life threatening" in the definition of "serious" refers to an event in which the subject is at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) ‚Ä¢ Requires inpatient hospi[INVESTIGATOR_1081] (hospi[INVESTIGATOR_22215] a baseline condition is not considered an AE) ‚Ä¢ Results in persistent or significant disability/incapacity (permanent or substantial disruption of a person‚Äôs ability to conduct normal life functions) ‚Ä¢ Is a congenital anomaly/birth defect ‚Ä¢ Is a medically important event that may not be immediately life threatening or result in death or hospi[INVESTIGATOR_486877]. Examples of such events include, but are not limited to, allergic bronchospasm requiring intensive treatment in an emergency room or at home; blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059]. Note: A spontaneous abortion will be considered an SAE and must be reported per Reporting of SAEs under Section [IP_ADDRESS]. [IP_ADDRESS] Assessment of Severity The severity assigned to an AE should be determined by [CONTACT_85210]. The categories described below should be used to estimate the severity of AEs: ‚Ä¢ Mild: Transient or mild discomfort; no limitation in activity; no medical intervention/therapy required ‚Ä¢ Moderate: Mild to moderate limitation in activity; some assistance may be needed; no or minimal medical intervention/therapy required ‚Ä¢ Severe: Marked limitation in activity; some assistance usually required; medical intervention/therapy required; hospi[INVESTIGATOR_486878]; may be incapacitating or life threatening [IP_ADDRESS] Assessment of Causality The PI [INVESTIGATOR_486879] ‚ÄúRelated‚Äù or ‚ÄúNot Related‚Äù. The following should be considered when assessing AE causality: ‚Ä¢ Related: There is at least a reasonable possibility that the AE/SAE is related to the study device. Reasonable possibility means that there is evidence to suggest a causal relationship between the study device and the AE. 
Clinical Trial Protocol ATM-[ADDRESS_625739]-2022 Confidential Page 17/25  
 ‚Ä¢ Not Related: There is little or no reasonable possibility that the AE/SAE is related to the study device. This assessment implies that the AE/SAE has little or no temporal relationship to the study device and/or a more likely or certain alternative etiology exists. [IP_ADDRESS] Reporting of Serious Adverse Events Adverse events classified as ‚Äúserious‚Äù require expeditious handling and reporting to ethica CRO within [ADDRESS_625740] Manager (or designate) within 24 hours of the PI‚Äôs awareness of the event. All SAEs must be reported via confirmed facsimile or email transmission and must be submitted on a written SAE report form signed by [CONTACT_978] [INVESTIGATOR_874] 24 hours of the PI‚Äôs awareness of the event. PIs should not wait to receive additional information to fully document the event before notifying ethica CRO of an SAE. If only limited information is initially available, follow-up reports are required. Additional relevant information such as hospi[INVESTIGATOR_85154]. The PI [INVESTIGATOR_486880], notably he/she should follow a subject with an SAE until the event has resolved or the condition has stabilized. This may imply that follow-up will continue after the subject has left the study, and that additional investigations may be requested by [CONTACT_1034]. When an SAE persists at the end of the study, the PI [INVESTIGATOR_284771]-up contacts with the subject until the PI/Sponsor agree the event is satisfactorily resolved and/or stabilized. [IP_ADDRESS] Pregnancy During the study, all female subjects of childbearing potential should be instructed to contact [CONTACT_978] [INVESTIGATOR_486881] (e.g., missed or late menstrual period). If a subject or PI [INVESTIGATOR_486882], the study device must be withheld until the results of laboratory pregnancy testing are available. If pregnancy is confirmed, the subject must not receive study device and must not be enrolled in the study. If pregnancy is suspected while the subject is receiving study device, the study device must immediately be withheld until the result of pregnancy testing is known. If pregnancy is confirmed, the study device will be permanently discontinued, and the subject will be followed until the pregnancy comes to term. All confirmed pregnancies must be reported via confirmed facsimile or email transmission and must be submitted on an Unanticipated Problems Reporting Form within 24 hours of the PI‚Äôs awareness of the pregnancy using the same reporting as procedure for an SAE under Section [IP_ADDRESS]. 10 STATISTICS There is no inferential statistical testing conducted for this study.  Descriptive data summaries will be prepared for all outcome variables.  For categorical parameters, the number and percentage of subjects/observations in each category will be presented. The denominator will be based on the number of subjects/observations appropriate for the purpose of analysis. For continuous parameters, descriptive statistics will 
Clinical Trial Protocol ATM-[ADDRESS_625741]-2022 Confidential Page 18/25  
 include n (number of subjects or observations), mean, standard deviation, median, and range. Two-sided 95% CIs will be provided for all study outcomes. 10.1 Sample Size Determination Approximately 20 subjects will be enrolled. This is a POC study and a formal sample size justification is not provided for this study. It is the opi[INVESTIGATOR_486870] a total of 20 subjects will be sufficient to achieve the objective of the study. 10.2 Assessment of Safety 10.2.1 Adverse Events All AEs occurring during the study will be recorded and classified on the basis of MedDRA terminology. Descriptions of AEs will include the date of onset, the date the AE ended, the severity of the AE, the relationship to study medication, the action taken regarding study medication usage, the action taken to treat the AE, and the outcome. All reported treatment-emergent AEs (TEAEs) and treatment-related events (TRAEs) will be summarized by [CONTACT_365473], system organ class, severity, seriousness, and relationship to study medication. AEs will be summarized by [CONTACT_85225], and by [CONTACT_486906]. Each subject will be counted only once within a system organ class or a preferred term by [CONTACT_264724]. 10.3 Analysis Populations 10.3.1 Intent-to-Treat (ITT) Population The modified Intent-to-Treat (mITT) Population is defined as all subjects who were enrolled and received at least one application with the study device. The mITT Population will be used for analyses of safety and effectiveness endpoints. 10.3.2 Per-Protocol (PP) Population A Per-Protocol (PP) Population will neither be defined nor analyzed. 10.3.[ADDRESS_625742] disposition will be provided which will include the numbers of subjects who enter, complete, and discontinue the study. The reasons for discontinuation will be included. 10.3.4 Protocol Deviations and Violations All protocol deviations and violations will be reported to the Sponsor and recorded throughout the study. A tabulation of protocol deviations will be included in the final study report. 10.3.5 Multicenter Issues Not applicable 10.3.6 Missing Data Imputations Data will be analyzed as observed; no imputations will be made for missing data. 10.3.[ADDRESS_625743]-2022 Confidential Page 19/25  
 10.4 Interim Analyses No interim analyses are planned. 11 QUALITY CONTROL AND QUALITY ASSURANCE 11.1 Study Monitoring An initiation webinar will be conducted with the PI [INVESTIGATOR_32528](s) by [CONTACT_166327]/or its designee. During this meeting, an extensive review and discussion of the protocol, all study procedures, source documents, and CRFs will be conducted. Evaluation scales will be reviewed extensively. The Clinical Project Manager(s) and Clinical Trial Associate(s) will be trained prior to study initiation. The conduct of the study will be closely monitored by [CONTACT_1034] (or designate) following GCP guidelines. The reports of these verifications will also be archived with the study report. In addition, inspections or on-site audits may be carried out by [CONTACT_123356]/or federal authorities. The PIs will allow the Sponsor's representatives and any regulatory agency to examine all study records, corresponding subject medical records, clinical dispensing records and storage area, and any other documents considered source documentation. The PIs agree to assist the representative, if required. 11.[ADDRESS_625744] follow the instructions exactly. A deviation from the protocol is an unintended and/or unanticipated departure from the procedures and/or processes approved by [CONTACT_486907]. Deviations usually have an impact on individual subjects or a small group of subjects and do not involve inclusion/exclusion or tolerability and cosmetic endpoint criteria. A protocol violation occurs when there is non-adherence to the protocol that results in a significant, additional risk to the subject, when the subject or PI [INVESTIGATOR_159021] (inclusion/exclusion criteria) and the subject was enrolled without prior Sponsor approval, or when there is non-adherence to ICH GCP guidelines. The issue of noncompliance may be either on the part of the subject, the PI, or the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_3483]. All protocol deviations and violations must be addressed in study subject source documents. A completed copy of the ethica CRO Inc. Protocol Deviation Form must be maintained in the regulatory file, as well as in the subject‚Äôs source document. Protocol deviations must be sent to the IRB per its guidelines. 
Clinical Trial Protocol ATM-[ADDRESS_625745]-2022 Confidential Page 20/[ADDRESS_625746] (IRB). A signed and dated notification of the IRB approval will be provided to the Sponsor and PI [INVESTIGATOR_282695]. The name [CONTACT_486917] [CONTACT_1201]. The PI [INVESTIGATOR_486883]. 12.[ADDRESS_625747] before any procedures or assessments are done and after the aims, methods, anticipated benefits, potential hazards, compensation and/or honoraria, and insurance arrangements in force are explained. It will also be explained to the subject that they are free to refuse entry into the study and free to withdraw from the study at any time without prejudice to future treatment. The Investigator will be available to respond as needed to questions raised by [CONTACT_2299]. Written and/or oral information about the study in a language understandable by [CONTACT_486908]. The subjects will be given the opportunity to discuss the procedure, risks, benefits, alternative therapi[INVESTIGATOR_486884] (or qualified designee) and have any and all questions answered to the subject‚Äôs satisfaction. The subject‚Äôs willingness to participate in the study will be documented in writing on a consent form, which will be signed by [CONTACT_262894]. The site will keep the original consent forms and copi[INVESTIGATOR_10047]. 12.[ADDRESS_625748] initials, demographics (including birthdates), medical histories, and prior concomitant medication uses, along with the name [CONTACT_486918] [INVESTIGATOR_486885]. Other than where necessary to meet regulatory requirements, all data collected in this study will be presented in tabulated (i.e., aggregate) form and listings containing information that could be used to identify an individual subject will not be included in any public disclosures of the study data or the study results. As part of the study database, study data will be stored at Equinix and Amazon Web Services facilities in [LOCATION_013] and Ireland that are SOC 1, SOC 2, ISO [ZIP_CODE], and FISMA examined and certified. Security monitoring includes biometric scanning protocols, continuous surveillance, and 
Clinical Trial Protocol ATM-[ADDRESS_625749]-2022 Confidential Page 21/25  
 24x7 production environment management. Data privacy complies with Canadian and US standards, as well as the European Union‚Äôs General Data Protection Regulation (GDPR).  The study database utilizes encryption to safeguard data and all data is durably stored with National Institute of Standards and Technology (NIST) approved ciphers, transport layer security (TLS) technology, and AES 256-bit at-rest encryption.  12.5 Data Monitoring Committee Not applicable. 12.6 Investigator Obligation The PI [INVESTIGATOR_49202], when signing the protocol, to adhere to the instructions and procedures described in it and thereby [CONTACT_220168] (GCP). 12.[ADDRESS_625750] follow the instructions exactly. Whenever possible, any planned deviations should be agreed to by [CONTACT_486909], with appropriate documentation of Sponsor approval prior to effecting the changes agreed upon. Any amendment to the protocol containing major modifications (particularly if it may involve an increased risk to the subjects) will be approved by [CONTACT_85239]. No change in the conduct of the study can be instituted without written approval from the Sponsor. 12.8 Confidentiality Regarding Study Subjects All the data furnished to the PI [INVESTIGATOR_43865]/her staff and all data obtained through this protocol will be regarded as confidential and proprietary in nature and will not be disclosed to any third party without written consent from the Sponsor. 12.[ADDRESS_625751] joint between the PI [INVESTIGATOR_486886], Inc. personnel.  All information, including but not limited to information regarding the study device or the Sponsor‚Äôs operations supplied by [CONTACT_486910] [INVESTIGATOR_262838], along with any data generated as a result of this study are considered confidential and remain the sole property of the Sponsor. The PI [INVESTIGATOR_486887]. The Sponsor or its designee is responsible for publicly registering this study on http://www.clinicaltrials.gov/ prior to initiating enrolment. 12.10 Financing and Insurance A separate financial agreement (Clinical Study Agreement) will be made between the Sponsor and the PI [INVESTIGATOR_12758]. ACOM Labs, Inc. will procure and maintain for the duration of the study a policy of insurance covering its liabilities in the conduct thereof. The certificate of insurance will be provided upon request.   
Clinical Trial Protocol ATM-[ADDRESS_625752]-2022 Confidential Page 22/25  
  13 APPENDICES Appendix A: Protocol Version History Appendix B: Adjustment of Visits and Assessments due to COVID-19   APPENDIX A: PROTOCOL VERSION HISTORY Version and Date Description v.1.0; 17-Oct-2022 Final Protocol v.2.0; 28-Oct-[ADDRESS_625753]-2022 Confidential Page 23/25  
 APPENDIX B: ADJUSTMENT OF VISITS AND ASSESSMENTS DUE TO COVID-[ADDRESS_625754] Manager (CPM) and IRB, as applicable. All protocol deviations which occur as a result of COVID-19 disruptions (including remote visits), will be differentiated from other deviations, and must be documented on the appropriate reporting forms/source document, and clearly annotated ‚Äúprotocol deviations due to COVID-19 illness/restrictions/etc.‚Äù. If the subject is unable or unwilling to come to the site due to COVID-19, the PI [INVESTIGATOR_486888]. The PI [INVESTIGATOR_486889]‚Äô safety and for monitoring all active subjects per protocol. PI [INVESTIGATOR_486890]. Should a subject develop any symptoms that could be related to COVID-[ADDRESS_625755] will be instructed to: ‚Ä¢ Contact [CONTACT_978] [INVESTIGATOR_91394] ‚Ä¢ Contact [CONTACT_486911]. The PI [INVESTIGATOR_486891]-up with the subject as needed but at least within [ADDRESS_625756]‚Äôs health and to obtain information on whether COVID-[ADDRESS_625757] has been diagnosed with COVID-19, the event will be reported as an AE. 2. Adjustment of Study Visits Telemedicine is understood as a possible solution due to COVID-19 disruption and it is not mandatory; if the situation allows it, study visits should be done in person. On-site Study Visit: If the local situation allows for conduct of on-site study visits, the PI [INVESTIGATOR_486892]/precautionary measures at the site to minimize or eliminate immediate hazards of viral transmission within and/or outside the clinical site premises.  Before any research activities occur on-site, both subjects and research staff should be screened for symptoms or risk of COVID-19 infection. Subjects should be pre-screened by [CONTACT_486912]-site study visit. If the local situation only allows for completion of some study procedures, the PI [INVESTIGATOR_486893]-person visit in order to maintain the viability and integrity of the research. The PI [INVESTIGATOR_486894] (e.g., medical history review, subject questionnaires) using telemedicine to minimize subject time on site and risk of exposure at the site. However, all efforts should be made to conduct all assessments at the scheduled visits, if possible. 
Clinical Trial Protocol ATM-[ADDRESS_625758]-2022 Confidential Page 24/25  
 Remote Study Visit: If the local situation does not allow for an on-site study visit to be conducted or if a subject does not wish to come to the study site due to COVID-[ADDRESS_625759]‚Äôs privacy, as would be done for a clinical visit: ‚Ä¢ Before the scheduled date of the visit: o The site personnel should determine if the subject can accommodate for video conferencing (e.g., internet access, PC, smartphone, video conference apps, etc.). o The PI [INVESTIGATOR_486895]‚Äôs verbal consent before proceeding with the visit and document it in the source document. The PI [INVESTIGATOR_486896]. o The site personnel should send all required study material to conduct the visit to the subject (e.g., UPTs, etc.). o A test call may also be completed with the subject prior to the appointment. ‚Ä¢ On the day of the scheduled visit:  o Both the PI/site delegate and the subject should confirm their respective identities with one another before engaging in a real-time video conference visit. For example, the site personnel will state their name [CONTACT_486919] [CONTACT_486913] (e.g., name [CONTACT_18131]) and a photo ID. o The date and time of the real-time video interaction, the location of the subject, and the location of the PI [INVESTIGATOR_486897]. o Remote collection of data by [CONTACT_976] [INVESTIGATOR_486898] 3 below. 3. Adjustment of Study Assessments  Informed consent: The following process will be followed for consenting a prospective subject remotely: ‚Ä¢ Each subject will be provided with an IRB-approved electronic consent form to aid in the consent discussion before the consent process begins.  ‚Ä¢ The PI [INVESTIGATOR_1238]/or site delegate will participate in the consent process via video conference. All parties must introduce themselves and their role in the consenting process.  ‚Ä¢ The consent form will be reviewed in detail and the subject will be invited to ask any questions and to have them addressed by [CONTACT_3476].   ‚Ä¢ If the subject is interested in joining the research study, the subject will be asked to electronically sign the consent document. ‚Ä¢ The PI [INVESTIGATOR_486899](es) will also provide electronic signatures as required. 
Clinical Trial Protocol ATM-[ADDRESS_625760]-2022 Confidential Page 25/25  
 ‚Ä¢ The site should ensure to obtain all electronic signature [CONTACT_486920]. The site should also provide a softcopy of the consent form to the subject and a hardcopy (in person or by [CONTACT_2319]).  Inclusion/Exclusion Criteria: The list of inclusion/exclusion criteria will be reviewed via video conference or phone call with the subject to confirm that they are eligible for the study. Data will be documented in the source documents and CRF. For potential subjects in a high-risk population for COVID-19 (e.g., 60 years old and older, with comorbidities such as diabetes, cardiovascular disease, respi[INVESTIGATOR_262840], etc.), deferring participation should be considered to minimize risks of exposure. Investigator Assessments of Efficacy and Safety: Investigator assessments of efficacy and safety can be conducted remotely via FaceTime and photos taken by [CONTACT_486914]/her phone.  Subject Assessments: Subject assessments of lesion pain cannot be conducted remotely. Subject Satisfaction Assessment can be conducted remotely and reviewed via video conference at each remote visit and reported in the source documents and CRF. Urine Pregnancy Tests: UPTs can be conducted remotely and reviewed via video conference at each remote visit and reported in the source documents and CRF. Demographics: Demographic information will be collected via video conference or phone call from the subject at the remote screening visit and will be documented in the source documents and CRF. Medical History / Concomitant Medications: Medical history and concomitant medications will be reviewed via video conference or phone call at each remote visit and reported in the source documents and CRF. Adverse Events: AEs will be reviewed remotely via video conference or phone call with the subject at each remote study visit. Any AE/SAE (including suspected / confirmed COVID-19 cases) elicited by a subject during a remote visit / phone call must be immediately captured, and all attempts should be done to capture the necessary clinical and medical information. Reporting of AEs and SAEs to the Sponsor and IRB should follow the protocol procedure and IRB requirements.  